navigating with insight

At Terns, we employ a proven, experience-driven approach to drug discovery and development. We focus our efforts on clinically validated and emerging mechanisms with strong human genetic rationale. Our approach centers around harnessing the substantial expertise of our team of high-level scientists with proven talent for bringing drugs to market. Their insights into disease biology and the paths that will most rapidly and successfully bring products to market underpin how we are reimagining known biology to address unmet medical needs, particularly in areas where existing therapies may fall short in terms of efficacy, safety, and/or tolerability.

Our advantage lies in efficiently collaborating with the scientific community. By maintaining a lean internal structure while being able to strategically scale up resources as needed, Terns can choose the most impactful indications and then leverage the best technologies for the job at hand to accelerate the development of superior small molecules. This nimble, experience-based model allows Terns to move faster than many companies that employ more traditional approaches, while maintaining focus on proven mechanisms that offer a higher probability of success across our oncology and metabolic disease programs.